The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
Medexpress.pl > Medexpress blogosphere (en)
Dr. Marek Derkacz, MBA
POTS in Long-COVID: The hidden culprit of chronic fatigue and dizziness
MedExpress Team
Dr n. med. Marek Derkacz
Published Dec. 27, 2024
With No Approved Treatments and Little Support, People With Long COVID Turn to Online Drug Markets
People are trying off-label medications, including some approved for treatment of HIV, hepatitis C or acute COVID-19.
December 17, 2024 • By Hannah Buttle and The Sick Times
Key points you should know:
American Family Physician Community Blog
Lilian White, MD
Posted on November 4, 2024
https://www.aafp.org/pubs/afp/afp-community-blog/entry/management-of-pots-due-to-long-covid.html
Linda Elsegood interviewing Andrea, a patient from the United States who has been taking low dose naltrexone (LDN) to manage her health concerns.
Experts Develop Multimodal Approach for Treating Long COVID, Other Post-Acute Infectious Syndromes
Pharmacy Times, September 13, 2024
By Luke Halpern, Assistant Editor
An international team of researchers has proposed a multimodal approach involving a mixture of physical and pharmacological interventions to treat post-acute infectious syndromes (PAIS), including the condition known as long COVID that affects survivors of SARS-CoV-2 infection, the virus that causes COVID-19.
News Medical Life Sciences
Genomic Press
Sep 4 2024
In a world still grappling with the aftermath of the COVID-19 pandemic, a team of international researchers has proposed a novel approach to treating the persistent symptoms that plague many survivors of viral infections. The study, published on 30 August 2024 in Brain Medicine (ISSN: 2997-2639, Genomic Press, New York), outlines a multimodal treatment strategy that could offer hope to millions suffering from post-acute infectious syndromes (PAIS), including the condition commonly known as Long COVID.
BY Kenny Cheng August 19, 2024
Yale Medicine
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia
Hiten Naik et al. Online issue publication May 13, 2024